{"id":11528,"date":"2022-04-04T15:10:38","date_gmt":"2022-04-04T15:10:38","guid":{"rendered":"https:\/\/dev.haugpartners.com\/?post_type=article&p=11528"},"modified":"2024-09-26T09:05:44","modified_gmt":"2024-09-26T09:05:44","slug":"ftcs-pharmaceutical-antitrust-suit-over-opioid-license-agreement-between-endo-and-impax-dismissed-because-patent-act-permits-exclusive-licenses","status":"publish","type":"article","link":"https:\/\/haugpartners.com\/article\/ftcs-pharmaceutical-antitrust-suit-over-opioid-license-agreement-between-endo-and-impax-dismissed-because-patent-act-permits-exclusive-licenses\/","title":{"rendered":"FTC\u2019s Pharmaceutical Antitrust Suit Over Opioid License Agreement Between Endo and Impax Dismissed Because Patent Act Permits Exclusive Licenses"},"featured_media":0,"template":"","categories":[98],"acf":[],"_links":{"self":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/article\/11528"}],"collection":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/article"}],"about":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/media?parent=11528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haugpartners.com\/wp-json\/wp\/v2\/categories?post=11528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}